Skip to main content

Advertisement

Log in

Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer

  • Original Article
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Background and aims

Vascular endothelial growth factor (VEGF) induces proliferation of endothelial cells, stimulates angiogenesis and increases vascular permeability. Epidermal growth factor (EGF) induces proliferation of epidermal cells and stimulates epidermal migration. Increased VEGF and EGF expression have been associated with poor clinical outcome in many malignancies. Several recent reports have shown overexpression of VEGF and EGF in papillary thyroid cancer (PTC). The study aimed to determine the intensity of expression of VEGF and EGF in patients with PTC and to find any correlation between the intensity of the expression and staging of the disease at the moment of surgery

Patients and methods

The study comprised a group of 48 consecutive patients with PTC who underwent radical surgery. The group consisted of 11, 25, eight and four patients at pT1N0M0, pT2N0M0, pT3N1M0 and pT4N1M0 stages, respectively. The control group was composed of 20 healthy bone marrow transplant donors, age-, gender- and BMI-matched with PTC patients. The immuno-chemiluminescence enzyme linked immunoassay (ELISA) method was used to determine the expression and level of VEGF and EGF in serum samples. Patients’ characteristics, serum levels of VEGF and EGF, final histology and pTNM were analysed.

Results

The mean serum level of VEGF and EGF was remarkably higher in PTC patients than in controls. A negative correlation between staging in pTNM classification and the mean serum VEGF level (r=−0.5168; P<0.05) as well as a positive correlation between staging in pTNM classification and the mean serum EGF level (r=0.6104; P<0.05) in PTC patients was observed.

Conclusions

Both VEGF and EGF play an important role in PTC growth. However, the intensity of their expression is variable, depending on the stage of the disease. The highest intensity of VEGF expression is characteristic for low-stage T1N0M0 disease, whereas the highest intensity of EGF expression is more often found at locally advanced pT3 and pT4N1M0 stages of the disease. Further long-term follow-up studies are required to demonstrate the prognostic value of VEGF and EGF in PTC, particularly in identification of patients with expected poor prognosis or shorter recurrence-free survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. American Cancer Society (1991) Cancer Stat 41:28–29

    Google Scholar 

  2. DeGroot LJ, Kaplan EL, McCormik M, Straus FH (1990) Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414–424

    Google Scholar 

  3. Schindler AM, van Melle G, Evequoz B, Scazziga B (1991) Prognostic factors in papillary carcinoma of the thyroid. Cancer 68:324–330

    CAS  PubMed  Google Scholar 

  4. Goretzki PE, Simon D, Dotzenrath C, Schulte KM, Röher HD (2000) Growth regulation of thyroid and thyroid tumors in humans. World J Surg 24:913–922

    Google Scholar 

  5. Falk SA (1997) Thyroid disease: endocrinology, surgery, nuclear medicine and radiotherapy. Lippincott, Williams & Wilkins, Philadelphia

    Google Scholar 

  6. Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 359:843–848

    Google Scholar 

  7. Yancopoulos GD, Klagsburn M, Folkman J (1998) Vasculogenesis, angiogenesis and growth factors: ephrins enter the fray at the border. Cell 93:661–664

    Google Scholar 

  8. Risau W (1997) Mechanism of angiogenesis. Nature 386:671–674

    Article  CAS  PubMed  Google Scholar 

  9. Carmeliet P (2000) Mechanism of angiogenesis and arteriogenesis. Nat Med 6:389–395

    Article  CAS  PubMed  Google Scholar 

  10. Balkwill F (2003) Chemokines biology in cancer. Semin Immunol 15:49–55

    Google Scholar 

  11. Reichlin M (1998) Systemic lupus erythematosus. In: Rose NR, Mackay IR (eds) The autoimmune diseases. Academic, Philadelphia, pp 1–37

    Google Scholar 

  12. Norrby W (1997) Angiogenesis: a new aspect relating to its initiation and control. Acta Pathol Microbiol Immunol Scand 105:417–437

    Google Scholar 

  13. Eliseenko VI, Skobelkin OK, Chegin VM (1998) Microcirculation and angiogenesis during wound healing by first and second intention. Bull Exp Biol Med 105:289–292

    Google Scholar 

  14. Maeda K, Chung YS, Ogawa Y (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77:858–863

    Google Scholar 

  15. Okada F, Rak J, St. Croix B, Lieubeau B, Kaya M, Roncari L, Shirasawa S, Sasazuki T, Kerbel RS (1998) Impact of oncogenes on tumor angiogenesis: mutant K-ras upregulation of VEGF/VPF is necessary but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci 95:3609–3614

    Google Scholar 

  16. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139–147

    Google Scholar 

  17. Goodman AL, Rone JD (1987) Thyroid angiogenesis: endotheliotropic chemoattractant activity from rat thyroid cell in culture. Endocrinology 121:2131–2140

    Google Scholar 

  18. Turner HE, Harris AL, Melmed SH, Wass JAH (2003) Angiogenesis in endocrine tumors. Endocr Rev 24:600–632

    Google Scholar 

  19. Rak J, Mrtsuhashi Y, Bayko L, Filmus J, Sasazuki T, Kerbel RS (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction or inhibition of tumor angiogenesis. Cancer Res 55:4575–4580

    CAS  PubMed  Google Scholar 

  20. Kerbel RS, Vilona-Petit A, Okada F, Rak J (1998) Establishing a link between oncogenes and tumor angiogenesis. Mol Med 4:286–295

    Google Scholar 

  21. Lin SY, Wang YY, Sheu WH (2003) Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer. Clin Endocrinol 58:513–518

    Google Scholar 

  22. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL, Tuttle RM (2001) Intensity of vascular endothelial growth factor expression associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129:552–558

    Google Scholar 

  23. Huang SM, Lee JC, Wu TJ, Chow NH (2001) Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg 25:302–306

    Google Scholar 

  24. Westermark K, Westermark B (1982) Mitogenic effect of epidermal growth factor on sheep thyroid cells in culture. Exp Cell Res 138:47–55

    Google Scholar 

  25. Westermark K, Karlsson A, Westermark B (1985) Thyrotropin modulates EGF receptor function in porcine thyroid follicle cells. Mol Cell Endocrinol 40:17–23

    Google Scholar 

  26. Westermark K, Karlsson FA, Westermark B (1983) Epidermal growth factor modulates thyroid growth and function in culture. Endocrinology 112:1680–1686

    Google Scholar 

  27. Masuda H, Sugenoya A, Kobayashi S, Kasuga Y, Iida F (1988) Epidermal growth factor receptor on human thyroid neoplasm. World J Surg 12:616–622

    Google Scholar 

  28. Alslen LA, Myking AO, Salvesen H, Varhaug JE (1993) Prognostic impact of EGF-receptor in papillary thyroid carcinoma. Br J Cancer 68:808–812

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Aleksander Konturek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Konturek, A., Barczyński, M., Cichoń, S. et al. Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer. Langenbecks Arch Surg 390, 216–221 (2005). https://doi.org/10.1007/s00423-004-0529-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00423-004-0529-0

Keywords

Navigation